This content is coming soon.

Open/close folder 
Key recommendations
  Diagnosis
  Treatment
  Acute promyelocytic leukaemia
  Pregnancy
  Transplantation
1. Introduction
2. Methods
3. Classification of acute myeloid leukaemia
  Minimum laboratory requirements for the diagnosis of AML
4. Prognostic Factors
5. Appropriate setting for the management of acute myeloid leukaemia
  5.1. Patient Support
6. Treatment of acute myeloid leukaemia
  6.1. General measures and supportive care
   6.1.2. Hyperleucocytosis
   6.1.3. Prevention of tumour lysis syndrome
  Recommendation
   6.1.4. Red cell transfusion support
   6.1.5. Platelet support
   6.1.6. Granulocyte transfusions
   6.1.7. Antibiotic and anti-infective therapy
   6.1.8. Bacterial infection
  Recommendation
   6.1.9. Fungal infection
   6.1.10. Growth factors
  Recommendations
  6.2. Treatment of younger adult patients
   6.2.1. Induction therapy
   6.2.2. Addition of other drugs
  Recommendations
   6.2.3. Postremission therapy
   6.2.4. Maintenance therapy
  6.3. Management of AML in patients who are pregnant
  Recommendations
  6.4. Management of extramedullary disease
  Recommendation
  6.5. Management of central nervous system disease
7. Acute promyelocytic leukaemia
  7.1. Diagnosis of APL
  7.2. Clinical management
   7.2.1. Induction
   7.2.2. Supportive care
   7.2.3. Consolidation
  7.4. Management of APL patients at high risk of relapse
  7.5. Management of relapse
  7.5. Role of molecular monitoring
  Recommendations
8. Management of relapsed AML
9. Transplantation in AML
  9.1. Transplantation in relapsed and refractory disease
  9.2. Reduced intensity conditioning allografts
  9.3. Haplo-identical transplants
  9.4. T-cell depletion
  9.5. Quality of life issues
  Recommendations
10. Acute myeloid leukaemia in the elderly
  10.1. Standard chemotherapy
  Recommendations
  10.2. Non-intensive (palliative) chemotherapy
  Recommendations
11. Conclusions
Disclaimer
Appendix 1
References